AerSale (ASLE) Q3 2026 Earnings Call Transcript

AerSale’s Q3 2026 revenue rose 28.6% year over year to $91.6 million, but adjusted EBITDA fell to $8.6 million from $9.5 million and gross margin contracted to 22.5% from 30.2%. The company posted a $15.0 million net loss, including a $13.4 million non-cash goodwill impairment, and used $42.7 million of operating cash year to date; quarter-end available liquidity was $23.1 million. Management expects fourth-quarter flight-equipment sales, including a planned $35 million Boeing 737 sale, to support liquidity and a stronger quarter, while expecting MRO facilities to become profitable EBITDA contributors starting in 2027.

Analysis

ASLE’s key issue is cash conversion, not the non-cash impairment. Growth is consuming working capital while borrowing-base headroom is thin; the expected equipment disposals therefore function as a liquidity event, not just an earnings catalyst. A delay, lower proceeds, or borrowing-base reduction would make the funding profile more fragile even if reported revenue remains strong.

The quality of growth is mixed: AerSafe demand tied to compliance can be lumpy, while MRO expansion only creates value if utilization rises faster than labor and facility costs. Management’s 2027 margin case depends on converting awarded work into completed checks, controlling turnover and labor costs, and absorbing fixed overhead. Aircraft held for lease also tie up capital until utilization and lease economics justify it. This is a different risk profile from a capital-light aftermarket supplier; parts shortages can help ASLE’s PMA opportunity, but OEMs retain certification and customer-approval advantages.

Near term, the market is likely to discount execution and liquidity more than the impairment. Over 1–3 months, closing the planned sales and demonstrating cash release are the main catalysts. Over 6–18 months, MRO throughput and recurring landing-gear work could improve earnings quality, but wage inflation, delayed aircraft work, or weak lease utilization could prevent margin recovery. Contrarian point: the impairment itself is not the thesis; the more consequential signal is that growth has not yet translated into gross-profit or cash-flow improvement. No valuation or share-price data are supplied, so a directional position is not well calibrated.

Key Decisions for Investors

• Keep ASLE on a catalyst watch rather than buying the revenue-growth narrative. Verify that planned fourth-quarter disposals close, proceeds are received, and revolver availability rises; a missed close or declining borrowing-base availability would invalidate the near-term liquidity case.
• For an existing position, size exposure against financing risk and monitor operating cash flow, revolver borrowings, and inventory/repair-cost investment—not adjusted EBITDA alone. Request the forthcoming 10-Q’s covenant headroom, borrowing-base terms, and asset-sale proceeds before adding.
• Reassess after the next report: a constructive signal requires sequential TechOps gross-margin recovery alongside higher throughput, not just revenue growth or management’s capacity targets. Failure to improve margins as shifts and awarded work ramp would weaken the 2027 earnings thesis.
• A defined-risk bearish trade is only a watch item: consider a put spread after checking option liquidity, implied volatility, and the share-price reaction if a sale slips or liquidity tightens. Without those market inputs, there is no defensible entry or risk/reward.